ORGANIC
LETTERS
2000
Vol. 2, No. 16
2459-2462
Asymmetric Synthesis of Actinoidic
Acid Derivatives
Sabine Boisnard, Luc Neuville, Miche`le Bois-Choussy, and Jieping Zhu*
Institut de Chimie des Substances Naturelles, CNRS, 91198 Gif-sur-YVette, France
Received May 26, 2000
ABSTRACT
Synthesis of fully protected actinoidic acid derivative 3 and selectively protected biaryl bisamino acid 4, intermediates for vancomycin total
synthesis, are reported.
Vancomycin (1) and related glycopeptide antibiotics have
attracted multidisciplinary interest for decades due to their
clinic importance.1 Indeed, together with teicoplanin, they
are the drug of last resort for the treatment of infections due
to methicillin-resistant Staphylococcus aureus and other
Gram positive organisms resistant to â-lactam antibiotics.
The complex molecular architecture and the recent emer-
gence of vancomycin-resistance phenomenon have rendered
them attractive synthetic targets.2 The intensive research
efforts have culminated in three landmark total syntheses of
vancomycin aglycon.3 In connection with our work aimed
at developing a new strategy toward the construction of AB-
COD rings,4 an efficient synthesis of suitably protected biaryl
diamino diacid units common to the 12-membered AB ring
of all glycopeptides of this family was required. Asymmetric
synthesis of such compounds was not trivial as one not only
has to construct a sterically congested biaryl moiety5 but also
has to introduce two very racemization prone aryl glycines.6
Controlling the axial chirality posed yet another synthetic
problem which has recently been addressed.7,8
Previously, we reported a synthesis of racemic actinoidic
acid derivative (2) employing Meyers’s oxazoline chemistry.9
With a view to developing a more convergent synthesis, we
decided to use a suitably protected D-phenylglycinol as a
nucleophilic partner in the intermolecular nucleophilic
(5) (a) Rama Rao, A. V.; Chakraborty, T. K.; Joshi, S. P. Tetrahedron
Lett. 1992, 33, 4045-4048. (b) Rama Rao, A. V. Reddy, K. L.; Reddy, M.
M. Tetrahedron Lett. 1994, 35, 5039-5042.
(6) Evans, D. A.; Ecrard, D. A.; Rychnovsky, S. D.; Fruh, T.; Whit-
tingham, W. G.; DeVries, K. M. Tetrahedron Lett. 1992, 33, 1189-1192.
(7) Lipshutz, B. H.; Peter Mu¨ller, P.; Leinweber, D. Tetrahedron Lett.
1999, 40, 3677-3680.
(1) (a) Williams, D. H.; Bardsley, B. Angew. Chem., Int. Ed. 1999, 38,
1173-1193. (b) Zhu, J. Exp. Opin. Ther. Pat. 1999, 9, 1005-1019.
(2) (a) Zhu, J. Synlett 1997, 133-144. (b) Nicolaou, K. C.; Boddy, C.
N. C.; Bra¨se, S.; Winssinger, N. Angew. Chem., Int. Ed. 1999, 38, 2096-
2152.
(3) (a) Evans, D. A.; Wood, M. R.; Trotter, B. W.; Richardson, T. I.;
Barrow, J. C.; Katz, J. L. Angew. Chem., Int. Ed. 1998, 37, 2700-2704;
2704-2708. (b) Nicolaou, K. C.; Natarajan, S.; Li, H.; Jain, N. F.; Hughes,
R.; Solomon, M. E.; Ramanjulu, J. M.; Boddy, C. N. C.; Takayanagi, M.
Angew. Chem., Int. Ed. 1998, 37, 2708-2714; 2714-2716; 2717-2719.
(c) Boger, D. L.; Miyazaki, S.; Kim, S. H.; Wu, J. H.; Loiseleur, O.; Castle,
S. L. J. Am. Chem. Soc. 1999, 121, 3226-3227. (d) For total synthesis of
vancomycin, see: Nicolaou, K. C.; Mitchell, H. J.; Jain, N. F.; Winssinger,
N.; Hughes, R.; Bando, T. Angew. Chem., Int. Ed. 1999, 38, 240-244.
(4) Neuville, L.; M. Bois-Choussy, Zhu, J. Tetrahedron Lett. 2000, 41,
1747-1751.
(8) (a) Miyano, S.; Tobita, M.; Hashimoto, H. Bull. Chem. Soc. Jpn.
1981, 54, 3522-3526. (b) Meyers, A. I.; Lutomski, K. A. J. Am. Chem.
Soc. 1982, 104, 879-881. (c) Wilson, J. M.; Cram, D. J. J. Am. Chem.
Soc. 1982, 104, 881-884. (d) Yamamoto, K.; Fukushima, H.; Nakazaki,
M. J. Chem. Soc., Chem. Commun. 1984, 1490-1491. (e) Hayashi, T.;
Hayashizaki, K.; Kiyoi, T.; Ito, Y. J. Am. Chem. Soc. 1988, 110, 8153-
8156. (f) Osa, T.; Kashiwagi, Y.; Yanagisawa, Y.; Bobbitt, J. M. J. J. Chem.
Soc., Chem. Commun. 1994, 2535-2537.
(9) Zhu, J.; Beugelmans, R.; Bigot, A.; Singh, G. P.; Bois-Choussy, M.
Tetrahedron Lett. 1993, 34, 7401-7404.
10.1021/ol006110s CCC: $19.00 © 2000 American Chemical Society
Published on Web 07/12/2000